CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study
Purpose To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments. Methods 367 liver cancer patients about to receive DEB-TACE treatment...
Gespeichert in:
| Veröffentlicht in: | Clinical & translational oncology 2019-02, Vol.21 (2), p.167-177 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 177 |
|---|---|
| container_issue | 2 |
| container_start_page | 167 |
| container_title | Clinical & translational oncology |
| container_volume | 21 |
| creator | Zhang, X. Zhou, J. Zhu, D.-D. Huang, J. Sun, J.-H. Li, T.-F. Shi, C.-S. Sun, Z.-C. Hou, Q.-M. Peng, Z.-Y. Yu, W.-Q. Ji, J.-S. Gu, W.-J. Zhou, G.-H. Xie, X.-X Guo, X.-H. Cao, G.-H. Yu, Z.-H. Xu, H.-H. Fang, J. Ying, S.-H. Hu, W.-H. Ji, W.-B. Han, J. Wu, X. Zheng, J.-P. Luo, J. Chen, Y.-T. Hu, T.-Y. Li, L. Hu, H.-J. Du, H.-J. Shao, G.-L. |
| description | Purpose
To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.
Methods
367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1–2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.
Results
There was no difference in complete response (CR) (
P
= 0.671) and objective response rate (ORR) (
P
= 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (
P
= 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1–3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1–3 month post-DEB-TACE (
P
= 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (
P
= 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.
Conclusion
DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments. |
| doi_str_mv | 10.1007/s12094-018-1902-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2070250514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2070250514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-5c907abcfdc72ca44ac7335f363ea12fca9cb55f9ee692b73e30ed9db4f3d9173</originalsourceid><addsrcrecordid>eNp9UU2O0zAUjhCI-YEDsEFv2VkE7DhpanZDKDBSJRYUiZ3lOM-tR47dsZ2icqg5BAfhLLhqYcnqWX7fn95XFK8oeUMJad9GWhFel4QuSspJVS6eFJd0znnJSNM8Pb9Jvfh-UVzFeE_y75zS58UFI4SwhpHL4ncnrTVfd1sMGH89whCmTYl2SsZtoEc5RJh9WL6_gRSkizIkDEZaUFscPY69t-anTMY7mK1vu-UNmAj4MGXNA6DWRhl0CaQbIEqNYBxYs8cASjqVxy5zMyDCD5O2MBitc4xMSGbECF7DLuDe-CmC8m6fN9kpux-tciCUaTyy34GEnH6yCXTwI3Tru1UHMU3D4UXxTEsb8eV5XhffPi7X3edy9eXTXXe7KhWr61Q2ipNW9koPqq2UrGupWsYazeYMJa20klz1TaM54pxXfcuQERz40NeaDZy27LqYnXR3wT9MGJMYTVRorXSY44uKtKRqSEPrDKUnqAo-xoBa7IIZZTgISsSxVnGqVeRaxbFWscic12f5qR9x-Mf422MGVCdAzCu3wSDu_RTyreJ_VP8AbnOzUw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2070250514</pqid></control><display><type>article</type><title>CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Zhang, X. ; Zhou, J. ; Zhu, D.-D. ; Huang, J. ; Sun, J.-H. ; Li, T.-F. ; Shi, C.-S. ; Sun, Z.-C. ; Hou, Q.-M. ; Peng, Z.-Y. ; Yu, W.-Q. ; Ji, J.-S. ; Gu, W.-J. ; Zhou, G.-H. ; Xie, X.-X ; Guo, X.-H. ; Cao, G.-H. ; Yu, Z.-H. ; Xu, H.-H. ; Fang, J. ; Ying, S.-H. ; Hu, W.-H. ; Ji, W.-B. ; Han, J. ; Wu, X. ; Zheng, J.-P. ; Luo, J. ; Chen, Y.-T. ; Hu, T.-Y. ; Li, L. ; Hu, H.-J. ; Du, H.-J. ; Shao, G.-L.</creator><creatorcontrib>Zhang, X. ; Zhou, J. ; Zhu, D.-D. ; Huang, J. ; Sun, J.-H. ; Li, T.-F. ; Shi, C.-S. ; Sun, Z.-C. ; Hou, Q.-M. ; Peng, Z.-Y. ; Yu, W.-Q. ; Ji, J.-S. ; Gu, W.-J. ; Zhou, G.-H. ; Xie, X.-X ; Guo, X.-H. ; Cao, G.-H. ; Yu, Z.-H. ; Xu, H.-H. ; Fang, J. ; Ying, S.-H. ; Hu, W.-H. ; Ji, W.-B. ; Han, J. ; Wu, X. ; Zheng, J.-P. ; Luo, J. ; Chen, Y.-T. ; Hu, T.-Y. ; Li, L. ; Hu, H.-J. ; Du, H.-J. ; Shao, G.-L.</creatorcontrib><description>Purpose
To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.
Methods
367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1–2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.
Results
There was no difference in complete response (CR) (
P
= 0.671) and objective response rate (ORR) (
P
= 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (
P
= 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1–3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1–3 month post-DEB-TACE (
P
= 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (
P
= 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.
Conclusion
DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.</description><identifier>ISSN: 1699-048X</identifier><identifier>EISSN: 1699-3055</identifier><identifier>DOI: 10.1007/s12094-018-1902-8</identifier><identifier>PMID: 30003530</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Aged ; Antibiotics, Antineoplastic - administration & dosage ; Chemoembolization, Therapeutic - methods ; Chemoembolization, Therapeutic - mortality ; Doxorubicin - administration & dosage ; Drug Carriers ; Female ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms - mortality ; Liver Neoplasms - therapy ; Male ; Medicine ; Medicine & Public Health ; Microspheres ; Middle Aged ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - therapy ; Oncology ; Research Article ; Treatment Outcome</subject><ispartof>Clinical & translational oncology, 2019-02, Vol.21 (2), p.167-177</ispartof><rights>Federación de Sociedades Españolas de Oncología (FESEO) 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-5c907abcfdc72ca44ac7335f363ea12fca9cb55f9ee692b73e30ed9db4f3d9173</citedby><cites>FETCH-LOGICAL-c344t-5c907abcfdc72ca44ac7335f363ea12fca9cb55f9ee692b73e30ed9db4f3d9173</cites><orcidid>0000-0002-0315-8896</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12094-018-1902-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12094-018-1902-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30003530$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, X.</creatorcontrib><creatorcontrib>Zhou, J.</creatorcontrib><creatorcontrib>Zhu, D.-D.</creatorcontrib><creatorcontrib>Huang, J.</creatorcontrib><creatorcontrib>Sun, J.-H.</creatorcontrib><creatorcontrib>Li, T.-F.</creatorcontrib><creatorcontrib>Shi, C.-S.</creatorcontrib><creatorcontrib>Sun, Z.-C.</creatorcontrib><creatorcontrib>Hou, Q.-M.</creatorcontrib><creatorcontrib>Peng, Z.-Y.</creatorcontrib><creatorcontrib>Yu, W.-Q.</creatorcontrib><creatorcontrib>Ji, J.-S.</creatorcontrib><creatorcontrib>Gu, W.-J.</creatorcontrib><creatorcontrib>Zhou, G.-H.</creatorcontrib><creatorcontrib>Xie, X.-X</creatorcontrib><creatorcontrib>Guo, X.-H.</creatorcontrib><creatorcontrib>Cao, G.-H.</creatorcontrib><creatorcontrib>Yu, Z.-H.</creatorcontrib><creatorcontrib>Xu, H.-H.</creatorcontrib><creatorcontrib>Fang, J.</creatorcontrib><creatorcontrib>Ying, S.-H.</creatorcontrib><creatorcontrib>Hu, W.-H.</creatorcontrib><creatorcontrib>Ji, W.-B.</creatorcontrib><creatorcontrib>Han, J.</creatorcontrib><creatorcontrib>Wu, X.</creatorcontrib><creatorcontrib>Zheng, J.-P.</creatorcontrib><creatorcontrib>Luo, J.</creatorcontrib><creatorcontrib>Chen, Y.-T.</creatorcontrib><creatorcontrib>Hu, T.-Y.</creatorcontrib><creatorcontrib>Li, L.</creatorcontrib><creatorcontrib>Hu, H.-J.</creatorcontrib><creatorcontrib>Du, H.-J.</creatorcontrib><creatorcontrib>Shao, G.-L.</creatorcontrib><title>CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study</title><title>Clinical & translational oncology</title><addtitle>Clin Transl Oncol</addtitle><addtitle>Clin Transl Oncol</addtitle><description>Purpose
To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.
Methods
367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1–2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.
Results
There was no difference in complete response (CR) (
P
= 0.671) and objective response rate (ORR) (
P
= 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (
P
= 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1–3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1–3 month post-DEB-TACE (
P
= 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (
P
= 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.
Conclusion
DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.</description><subject>Adult</subject><subject>Aged</subject><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Chemoembolization, Therapeutic - mortality</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Carriers</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microspheres</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Oncology</subject><subject>Research Article</subject><subject>Treatment Outcome</subject><issn>1699-048X</issn><issn>1699-3055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU2O0zAUjhCI-YEDsEFv2VkE7DhpanZDKDBSJRYUiZ3lOM-tR47dsZ2icqg5BAfhLLhqYcnqWX7fn95XFK8oeUMJad9GWhFel4QuSspJVS6eFJd0znnJSNM8Pb9Jvfh-UVzFeE_y75zS58UFI4SwhpHL4ncnrTVfd1sMGH89whCmTYl2SsZtoEc5RJh9WL6_gRSkizIkDEZaUFscPY69t-anTMY7mK1vu-UNmAj4MGXNA6DWRhl0CaQbIEqNYBxYs8cASjqVxy5zMyDCD5O2MBitc4xMSGbECF7DLuDe-CmC8m6fN9kpux-tciCUaTyy34GEnH6yCXTwI3Tru1UHMU3D4UXxTEsb8eV5XhffPi7X3edy9eXTXXe7KhWr61Q2ipNW9koPqq2UrGupWsYazeYMJa20klz1TaM54pxXfcuQERz40NeaDZy27LqYnXR3wT9MGJMYTVRorXSY44uKtKRqSEPrDKUnqAo-xoBa7IIZZTgISsSxVnGqVeRaxbFWscic12f5qR9x-Mf422MGVCdAzCu3wSDu_RTyreJ_VP8AbnOzUw</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Zhang, X.</creator><creator>Zhou, J.</creator><creator>Zhu, D.-D.</creator><creator>Huang, J.</creator><creator>Sun, J.-H.</creator><creator>Li, T.-F.</creator><creator>Shi, C.-S.</creator><creator>Sun, Z.-C.</creator><creator>Hou, Q.-M.</creator><creator>Peng, Z.-Y.</creator><creator>Yu, W.-Q.</creator><creator>Ji, J.-S.</creator><creator>Gu, W.-J.</creator><creator>Zhou, G.-H.</creator><creator>Xie, X.-X</creator><creator>Guo, X.-H.</creator><creator>Cao, G.-H.</creator><creator>Yu, Z.-H.</creator><creator>Xu, H.-H.</creator><creator>Fang, J.</creator><creator>Ying, S.-H.</creator><creator>Hu, W.-H.</creator><creator>Ji, W.-B.</creator><creator>Han, J.</creator><creator>Wu, X.</creator><creator>Zheng, J.-P.</creator><creator>Luo, J.</creator><creator>Chen, Y.-T.</creator><creator>Hu, T.-Y.</creator><creator>Li, L.</creator><creator>Hu, H.-J.</creator><creator>Du, H.-J.</creator><creator>Shao, G.-L.</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0315-8896</orcidid></search><sort><creationdate>20190201</creationdate><title>CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study</title><author>Zhang, X. ; Zhou, J. ; Zhu, D.-D. ; Huang, J. ; Sun, J.-H. ; Li, T.-F. ; Shi, C.-S. ; Sun, Z.-C. ; Hou, Q.-M. ; Peng, Z.-Y. ; Yu, W.-Q. ; Ji, J.-S. ; Gu, W.-J. ; Zhou, G.-H. ; Xie, X.-X ; Guo, X.-H. ; Cao, G.-H. ; Yu, Z.-H. ; Xu, H.-H. ; Fang, J. ; Ying, S.-H. ; Hu, W.-H. ; Ji, W.-B. ; Han, J. ; Wu, X. ; Zheng, J.-P. ; Luo, J. ; Chen, Y.-T. ; Hu, T.-Y. ; Li, L. ; Hu, H.-J. ; Du, H.-J. ; Shao, G.-L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-5c907abcfdc72ca44ac7335f363ea12fca9cb55f9ee692b73e30ed9db4f3d9173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Chemoembolization, Therapeutic - mortality</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Carriers</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microspheres</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Oncology</topic><topic>Research Article</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, X.</creatorcontrib><creatorcontrib>Zhou, J.</creatorcontrib><creatorcontrib>Zhu, D.-D.</creatorcontrib><creatorcontrib>Huang, J.</creatorcontrib><creatorcontrib>Sun, J.-H.</creatorcontrib><creatorcontrib>Li, T.-F.</creatorcontrib><creatorcontrib>Shi, C.-S.</creatorcontrib><creatorcontrib>Sun, Z.-C.</creatorcontrib><creatorcontrib>Hou, Q.-M.</creatorcontrib><creatorcontrib>Peng, Z.-Y.</creatorcontrib><creatorcontrib>Yu, W.-Q.</creatorcontrib><creatorcontrib>Ji, J.-S.</creatorcontrib><creatorcontrib>Gu, W.-J.</creatorcontrib><creatorcontrib>Zhou, G.-H.</creatorcontrib><creatorcontrib>Xie, X.-X</creatorcontrib><creatorcontrib>Guo, X.-H.</creatorcontrib><creatorcontrib>Cao, G.-H.</creatorcontrib><creatorcontrib>Yu, Z.-H.</creatorcontrib><creatorcontrib>Xu, H.-H.</creatorcontrib><creatorcontrib>Fang, J.</creatorcontrib><creatorcontrib>Ying, S.-H.</creatorcontrib><creatorcontrib>Hu, W.-H.</creatorcontrib><creatorcontrib>Ji, W.-B.</creatorcontrib><creatorcontrib>Han, J.</creatorcontrib><creatorcontrib>Wu, X.</creatorcontrib><creatorcontrib>Zheng, J.-P.</creatorcontrib><creatorcontrib>Luo, J.</creatorcontrib><creatorcontrib>Chen, Y.-T.</creatorcontrib><creatorcontrib>Hu, T.-Y.</creatorcontrib><creatorcontrib>Li, L.</creatorcontrib><creatorcontrib>Hu, H.-J.</creatorcontrib><creatorcontrib>Du, H.-J.</creatorcontrib><creatorcontrib>Shao, G.-L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical & translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, X.</au><au>Zhou, J.</au><au>Zhu, D.-D.</au><au>Huang, J.</au><au>Sun, J.-H.</au><au>Li, T.-F.</au><au>Shi, C.-S.</au><au>Sun, Z.-C.</au><au>Hou, Q.-M.</au><au>Peng, Z.-Y.</au><au>Yu, W.-Q.</au><au>Ji, J.-S.</au><au>Gu, W.-J.</au><au>Zhou, G.-H.</au><au>Xie, X.-X</au><au>Guo, X.-H.</au><au>Cao, G.-H.</au><au>Yu, Z.-H.</au><au>Xu, H.-H.</au><au>Fang, J.</au><au>Ying, S.-H.</au><au>Hu, W.-H.</au><au>Ji, W.-B.</au><au>Han, J.</au><au>Wu, X.</au><au>Zheng, J.-P.</au><au>Luo, J.</au><au>Chen, Y.-T.</au><au>Hu, T.-Y.</au><au>Li, L.</au><au>Hu, H.-J.</au><au>Du, H.-J.</au><au>Shao, G.-L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study</atitle><jtitle>Clinical & translational oncology</jtitle><stitle>Clin Transl Oncol</stitle><addtitle>Clin Transl Oncol</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>21</volume><issue>2</issue><spage>167</spage><epage>177</epage><pages>167-177</pages><issn>1699-048X</issn><eissn>1699-3055</eissn><abstract>Purpose
To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.
Methods
367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1–2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.
Results
There was no difference in complete response (CR) (
P
= 0.671) and objective response rate (ORR) (
P
= 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (
P
= 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1–3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1–3 month post-DEB-TACE (
P
= 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (
P
= 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.
Conclusion
DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>30003530</pmid><doi>10.1007/s12094-018-1902-8</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-0315-8896</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1699-048X |
| ispartof | Clinical & translational oncology, 2019-02, Vol.21 (2), p.167-177 |
| issn | 1699-048X 1699-3055 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2070250514 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antibiotics, Antineoplastic - administration & dosage Chemoembolization, Therapeutic - methods Chemoembolization, Therapeutic - mortality Doxorubicin - administration & dosage Drug Carriers Female Humans Kaplan-Meier Estimate Liver Neoplasms - mortality Liver Neoplasms - therapy Male Medicine Medicine & Public Health Microspheres Middle Aged Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - therapy Oncology Research Article Treatment Outcome |
| title | CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A48%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CalliSpheres%C2%AE%20drug-eluting%20beads%20(DEB)%20transarterial%20chemoembolization%20(TACE)%20is%20equally%20efficient%20and%20safe%20in%20liver%20cancer%20patients%20with%20different%20times%20of%20previous%20conventional%20TACE%20treatments:%20a%20result%20from%20CTILC%20study&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=Zhang,%20X.&rft.date=2019-02-01&rft.volume=21&rft.issue=2&rft.spage=167&rft.epage=177&rft.pages=167-177&rft.issn=1699-048X&rft.eissn=1699-3055&rft_id=info:doi/10.1007/s12094-018-1902-8&rft_dat=%3Cproquest_cross%3E2070250514%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2070250514&rft_id=info:pmid/30003530&rfr_iscdi=true |